Local view for "http://purl.org/linkedpolitics/eu/plenary/2012-01-19-Speech-4-291-988"
| Predicate | Value (sorted: default) |
|---|---|
| rdf:type | |
| dcterms:Date | |
| dcterms:Is Part Of | |
| dcterms:Language | |
| lpv:document identification number |
"en.20120119.24.4-291-988"2
|
| lpv:hasSubsequent | |
| lpv:speaker | |
| lpv:spokenAs | |
| lpv:translated text |
"I supported the agreement at second reading on the regulation stipulating the conditions under which biocidal products can be placed on the market because, in spite of fairly tough negotiations, a satisfactory result has been reached in terms of industrial competitiveness and protection for the users of these products and the environment. I think that introducing an EU-level authorisation procedure is one of the most important advances. Although I would have preferred the agreement to be implemented more quickly than the three-step approach advocated in the agreement and justified by the need to ensure the optimum operation of the European Chemicals Agency, I still believe that this procedure, along with the simplified procedure for low risk products, will reduce considerably the costs which will be incurred by the industry for authorising new products. This will also promote innovation in this area, as it will encourage new products to be placed on the market which are more effective and less harmful to the environment and users. Last but not least, I am pleased that the members of the Council have accepted Parliament’s request to avoid the duplication of animal testing when such tests have already been carried out."@en1
|
Named graphs describing this resource:
The resource appears as object in 2 triples